Summary
Jonathan Allan, General Counsel and Corporate Secretary at Stoke Therapeutics (NASDAQ: STOK), executed a scripted insider sale on March 20, 2026, disposing of 9,293 common shares under an established 10b5-1 trading plan. The combined transactions produced proceeds of $313,038. After the disposition, Allan directly holds 19,543 shares of the company.
Transaction details
The sale was split across two trades. The larger block of 8,692 shares was sold at a weighted average price of $33.6354, with executed prices ranging from $33.33 to $34.28. A subsequent sale of 601 shares carried a weighted average price of $34.4079, with execution prices between $34.34 and $35.12. Together, those sales accounted for the entire 9,293-share disposition that generated $313,038 in proceeds.
Insider holding after sale
Following these transactions, Allan retains direct ownership of 19,543 Stoke Therapeutics shares.
Market context
The insider activity occurred while STOK was trading at $32.18, a price point noted in the report as close to its 52-week high of $40.22. According to InvestingPro data cited in the report, the stock has returned 303% over the previous 12 months and is trading slightly above a Fair Value estimate of $31.35. The InvestingPro analysis referenced additional research features, including eight ProTips and a broader Pro Research Report highlighting Stoke’s cash position and recent price momentum.
Analyst and corporate developments
Analyst coverage and company-level actions were also detailed. Canaccord Genuity raised its price target for Stoke Therapeutics to $60 from $36 and maintained a Buy rating, citing higher revenue assumptions for the company's lead candidate, zorevunersen, which the firm projects could act as a disease-modifying therapy for Dravet syndrome. Guggenheim initiated coverage with a Buy rating and a $60 price target, emphasizing zorevunersen’s potential to address the underlying cause of Dravet syndrome. Cantor Fitzgerald reiterated an Overweight rating as Stoke engages with the U.S. Food and Drug Administration on discussions about expedited regulatory pathways for zorevunersen.
Executive compensation action
Separately, Stoke’s board approved a discretionary cash bonus of $697,125 for CEO Ian F. Smith. The bonus recognizes Smith’s leadership since he became interim CEO in March 2025 and was named permanent CEO in October 2025, and reflects the company’s reported clinical and financial performance during his tenure.
What this reflects
Taken together, the insider sale, recent analyst positioning, the board-approved CEO bonus, and ongoing FDA discussions underscore the market and management focus on Stoke’s lead asset, zorevunersen. These elements have coincided with notable share-price gains over the past year, according to the cited InvestingPro metrics.
Note: The above information reports the announced insider transaction, market data and analyst actions as described in the source material. Where details were limited in the source, they are reported here as presented.